LGG subtypes based on the activity changes of immunologic and hallmark gene sets in cancer

Sihan Chen (csh940903@outlook.com)
Taikang Ningbo Hospital

Research Article

Keywords: Glioma, TCGA, GSEA, GSVA, Cancer, TME

Posted Date: January 31st, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1276834/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose: When glioma is in WHO grade II-III, glioma is of low grade. Gliomas in this period have the opportunity for surgical treatment and can be treated with a range of targeted therapies to enhance patient survival.

Methods: In this study, we downloaded low-grade glioma data from TCGA database and GSEA database. Cancer subtypes were classified by GSVA enrichment method.

Results: By GSVA enrichment analysis, we obtain three low-grade gliomas (LGG) cancer subtypes. After further survival prognosis analysis and biological function analysis, we obtained 21 tumor microenvironment gene sets and 17 core genes that affect patients’ survival prognosis, and these genes have the potential to become targets for targeted therapies and disease detection.

Conclusion: We screened a total of 21 gene sets through a series of enrichment analyses, statistical and prognostic analyses, etc. Among them, 17 core genes were identified, namely: TOP2A, KIF20A, CCNB2, AURKA, KIF11, CDK1, BUB1B, CCNA2, BUB1, CDC20, CDC8, TPX2, KIF2C, POLA2, POLE2, POLA1 and POLE. TOP2A.

1. Introduction

Glioma is the most common primary tumor of the brain, which originates from glial cells. Gliarial cells nourish and support neuronal cells, but under the induction of some physicochemical factors, neuronal cells can deteriorate into glioma cells[1]. Numerous studies have confirmed that the progression of glioma is closely related to the Tumor microenvironment (TME). The tumor microenvironment can induce differentiation of normal cells into tumor cells through a series of physicochemical mechanisms, so the current study focused on the direct relationship between microenvironmental cells and glioma[1-3]. According to the World Health Organization (WHO), gliomas with pathological grading in grades II and III are defined as low-grade gliomas (LGG), in which patients could be treated surgically and have the possibility to further improve the treatment outcome. In the current study we are dedicated to the study of LGG Tumor microenvironment constitutive genes, working to find targets to improve LGG survival prognosis and detect predictive genes for LGG disease[4]. With the establishment of databases such as TCGA, more and more studies are using big data to analyze therapeutic targets as well as genes available for screening. In the current study, enrichment analysis was used to screen tumor microenvironment-related genes and classify LGG into three subtypes, and finally to screen the gene set and core genes that affect the survival prognosis of LGG patients[5]. In conclusion, we mined 21 sets of microenvironmental gene sets and 17 core genes affecting LGG survival prognosis through a series of statistical analysis and enrichment analysis[6].

2. Methods

2.1 Data Collection

For the present study, the included genetic and clinical data were downloaded from the TCGA database. We collected 529 cases of gene expression data, and 515 cases of clinical data from LGG patients. In addition, we downloaded 4922 immune gene datasets from Gene Set Enrichment Analysis (GSEA) (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp) [7].

2.2 Functional enrichment analysis using GSVA

Gene set variation analysis (GSVA) can be used to assess the degree of enrichment of a specific gene set in a sample population and thus observe changes in the activity of a set of gene sets. Enrichment analysis of the above gene set was performed using GSVA to assess the relevant biological activity [8].

2.3 Statistical analysis

All statistical analyses were performed with R software (version 4.1.2). p-values <0.05 were considered statistically significant. p<0.01 was considered a significant difference. heatmap and subtype classification of LGG samples were analyzed by the Heatmap and CancerSubtys packages of the R software. Apply NMF package to cancer genomic dataset for NMF. Cox regression model (COX) was used to screen for sets of genes that potentially affect patient survival prognosis. riskscore = \sum \text{Exp}_i \cdot \text{Coe}_i, where \text{Exp}_i indicated the expression level for each gene and the \text{Coe}_i indicated the corresponding multivariable Cox regression coefficient.

2.4 Protein Interaction Networks and Biological Function Networks

STRING (https://cn.string-db.org/) was used to analyze the interaction links between genes, and then the core genes of the protein interaction network were obtained using the plug-in MCODE of Cytoscape software (version 3.9.0). the Clue GO plug-in was used to generate the biological functional interaction network [9].

3. Results
3.1 Immunological activity of the hallmark gene set in the LGG samples.

Because GSVA can detect even subtle pathway activity, we use GSVA to detect pathway activity in selected sets of genes. We downloaded 4922 immunologically relevant genes from GSEA to provide a comprehensive picture of the changes in the immune activity of LGG. gene expression of LGG was downloaded from the TCGA database (from 529 LGG patients). Figure 1 is a diagram of our research process. Immunological microarrays can define the immunological genome. The gene expression of LGG was visualized by heatmap (Figure 2).

After obtaining gene expression amounts, we tried to classify LGG patients into different subtypes. Because survival prognosis data were available for only 515 patients in TCGA, after collation, we screened the data from 508 patients who had both gene expression data and clinically relevant data. Using the COX regression model in Nonnegative matrix factorization and CancerSubtypes package, we classified LGG into 3 subtypes (Figure 3E). The average Silhouette width value was 0.88 (the closer the value is to 1 the more accurate it is, and 0.88 is already a very accurate value) (Figure 3D). The factoextra package of R software can classify cases into the best groups (Figure 3A and 3B). Kaplan-Meierplotter analysis was used to construct a survival model. Among the three subtypes of LGG, subtype 1 had the worst prognosis, subtype 2 was slightly better, while subtype 3 had the best prognosis among the three subtypes (Figure 3C).

3.2 Relationship between LGG tumor subtypes and clinical information.

We visualized the relationship between clinical information and LGG gene expression by heat map. The results showed that cancer subtypes were strongly correlated with LGG grade, P < 0.001, and cancer subtypes were correlated with patient age, P < 0.05. The above two clinical information were statistically significant between different cancer subtypes. (Figure4) The specific information is shown in Table1. Visualization of the differential gene sets of the three cancer subtypes by Venn diagram showed that there were 74 differential gene sets among the three cancer subtypes (Figure 5). Visual analysis of these 74 gene sets showed significant differences in the expression of the 74 gene sets in the three different cancer subtypes (Figure6).

3.3 Linking gene expression and survival prognosis of LGG patients.

The COX regression analysis model allows a good assessment of the relationship between variables on survival and posterior. By COX regression analysis, we concluded that a total of 21 gene sets were associated with the survival prognosis of LGG patients (Figure7). the risk scores derived from COX regression were divided into high and low risk based on median, with the high-risk group having a significantly worse survival prognosis than the low-risk group (Figure8).

3.4 Screening and biological function analysis of core genes.

Searching the above 21 sets of gene sets in GSEA's, we obtained 4107 immunology-related genes. The protein interaction network was constructed by STRING database (https://cn.string-db.org/). The results were imported into Cytoscape (version 3.9.0), and the biological functions of the protein interaction network were analyzed using the Clue Go plugin (Figure9 A). Finally, the core modules and core genes in the protein interaction network were identified using the MCODE plugin. The results showed that a total of 17 core genes and 2 core modules were filtered out. They are TOP2A, KIF20A, CCNB2, AURKA, KIF11, CDK1, BUB1B, CCNA2, BUB1, CDC20, CDC2A8, TPX2, KIF2C, POLA2, POLE2, POLA1 and POLE (Figure9 B, C).

4. Discussion

Glioma is a common primary tumor of the central nervous system. The microenvironment of the glioma tissue area consists of tumor cells, immune cells and various factors secreted by them. Among them, various factors secreted by tumor cells or immune cells, such as growth factors, chemokines, pro-inflammatory factors and anti-inflammatory factors, form the microenvironmental network, which interact with each other to regulate and influence the process of tumor[10].

Gliial cells support nerve cells in their associated neural activities and keep them healthy. However, glial cells can also give rise to a malignant tumor, glioma, which is the most common primary malignant tumor of the brain. The World Health Organization classifies gliomas as grades I, II, III, and IV. II, III are classified as lower-grade gliomas (LGGs). Gliomas can present with many symptoms, such as Headaches, Mental Status Changes, Motor/Movement Changes, Seizures, and Sensory Changes. The differences in symptoms are mainly related to the location where the glioma occurs. In addition to causing many painful symptoms, gliomas can also greatly reduce the survival time of patients. However, there is still a great deal of research into the treatment and detection of gliomas in the brain. With the establishment of databases like TCGA and GSEA, more and more studies are using big data and AI to analyze many valuable research results. Many studies have now found that immunologically relevant activities of tumors, play an important role in both suppressing and promoting tumor progression. The present study will focus on immunology-related activities to analyze LGG-related mechanisms and clinical prognosis. In this study, we used a database with each analysis software to analyze the big data of LGG patients, aiming at obtaining some gene sets that can predict the prognosis of patients’ survival. These gene sets are expected to be new targets for detection or treatment.

In this study, we screened the gene expression transcripts of LGG in TCGA's GDC database and downloaded their corresponding clinical data. We downloaded gene expression data for a total of 529 patients, but their corresponding clinical data were available for only 515 cases. Therefore, we deleted 14 cases of gene expression data without clinical data. We downloaded immune-related gene sets from GSEA and then enriched 3 different
cancer subtypes by GSVA. Among the three different cancer subtypes, subtype 1 has the worst survival prognosis, subtype 3 has the best prognosis, and subtype 2 is in between. The closer the Silhouette width value is to 1, the higher the accuracy of the model is represented. Among the three different cancer subtypes, the highest Silhouette width value was 0.93 for subtype 1 and subtype 2, and 0.83 for subtype 3. The average Silhouette width value of the three subtypes was 0.88, which represents the high accuracy of our model. With the nonnegative matrix factorization (NMF) method, we can clearly see that the 3 cancer subtypes have different Clustering displays. This also represents that there is a significant difference in gene expression among the three cancer subtypes (Figure 3). The heat map shows that there are significant differences in gene expression profiles among the three cancer subtypes (Figure 4). According to the analysis, the main reasons for this difference were the age of the patients and the grade of the cancer. Using the Venn diagram, we can find 74 common differential gene sets for the 3 cancer subtypes (Figure 5). Also, the heat map can show that the three cancer subtypes have significantly different expressions in these 74 gene sets (Figure 6). By COX regression analysis, we obtained 21 gene sets that affect the prognosis of LGG patients (Table2). K-M curves allow analysis of the relationship between gene set expression and patient survival prognosis. By the median of gene set expression, we divided them into high-risk and low-risk groups, and the results showed that in the 21 gene sets, the survival prognosis of the high-risk group was significantly worse than that of the low-risk group (Figure 7). The gene set expression was multiplied by the Coef value of the gene set by COX regression analysis, relying on the median to classify them into high-risk and low-risk groups. K-M curve analysis showed that the survival prognosis of the high-risk group was significantly worse than that of the low-risk group (Figure 8). We listed the gene data (4107) from 21 gene sets to construct their biological function enrichment network. The results show that the core functions of the network are: outer kinetochore\textsuperscript{\textregistered}alpha DNA polymerase: primase complex\textsuperscript{\textregistered}attachment of mitotic spindle microtubules to kinetochore\textsuperscript{\textregistered}positive regulation of chromosome separation\textsuperscript{\textregistered}Cell cycle\textsuperscript{\textregistered}spindle midzone\textsuperscript{\textregistered}mitotic spindle midzone\textsuperscript{\textregistered}protein localization to chromosome, centromeric region\textsuperscript{\textregistered}protein localization to condensed chromosome. The 21 gene sets were placed into the STRING database and their protein interaction networks were analyzed. The core modules in the protein interaction network were then analyzed by the Cytoscape (3.9.0) plugin MCODE. Finally, we analyzed 17 core genes, which are: TOP2A, KIF20A, CCNB2, AURKA, KIF11, CDK1, BUB1B, CCNA2, BUB1, CDC20, CDC8, TPX2, KIF2C, POLA2, POLE2, POLA1 and POLE. TOP2A is a major target for many targeted therapies, and it is overexpressed in many tumors. It has been shown that inhibition of TOP2A expression inhibits the proliferation of tumor cells in cellular experiments. However, the research on this gene has been limited to basic experiments and has not been well applied to clinical studies. [11, 12]. A related study showed that tumor specimens from patients with glioma were used for gene sequencing and showed that patients with increased KIF20A expression had a poorer survival prognosis. However, the study of this gene in glioma remains to be further explored[13, 14]. CCNB2 is a member of the cell cycle protein family, specifically the B-type cell cycle proteins. Current studies support that LGG patients with high CCNB2 expression have a significantly worse survival prognosis than those with low CCNB2 expression. However, the exact mechanism is not clear. It is simply described to be closely related to the tumor microenvironment[15-18]. AURKA and KIF11 are used as a target in many tumors for targeted therapy, and these genes are also microenvironment constituent genes of tumors[19-22]. CKD1 has not been studied much in glioma. It has been reported that gliomas can develop resistance to Temozolomide by immune escape through the CDK1/survivin signaling pathway[23]. BUB1B may provide a marker to predict aggressive and effective drug response[24]. CCNA2 has been little studied in glioma, and its mechanism of action in glioma needs to be further investigated[18]. Glioma cells proliferate and rely on the BUB1B / BubR1 pathway for mitosis[25]. CDC20 overexpression and its associated gene modules were characteristically elevated, signifying increased genomic instability in gliomas[26]. At present, there are few studies of other core genes in glioma to conclude the mechanisms involved.

Conclusion

In summary, we screened a total of 21 gene sets through a series of enrichment analyses, statistical and prognostic analyses, etc. Among them, 17 core genes were identified, namely: TOP2A, KIF20A, CCNB2, AURKA, KIF11, CDK1, BUB1B, CCNA2, BUB1, CDC20, CDC8, TPX2, KIF2C, POLA2, POLE2, POLA1 and POLE. TOP2A.

Abbreviations

COX: Cox regression model; GSVA: Gene set variation analysis; LGG: low-grade gliomas; WHO: World Health Organization; TME: tumor microenvironment; OS: overall survival; GSEA: gene set enrichment analysis; HR: hazard ratio; TCGA: The Cancer Genome Atlas

Declarations

Acknowledgements

Thanks to the Taikang Ningbo Hospital for supporting this research.

Author contributions

Sihan Chen guided and revised the manuscript. All authors contributed equally to this manuscript.

Competing Interests

The authors declare no competing interests.

Ethics approval and consent to participate
There were no human subject studies, cell, tissue, or animal studies. No ethical requirements are involved.

**Data Availability Statement**

The submitting author has read and agreed to this statement on behalf of all authors on this paper.

**References**

1. Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B: Immune microenvironment of gliomas. Laboratory investigation; a journal of technical methods and pathology 2017, 97(5):498–518.

2. Ma Q, Long W, Xing C, Chu J, Luo M, Wang HY, Liu Q, Wang RF: Cancer Stem Cells and Immunosuppressive Microenvironment In Glioma. Frontiers in immunology 2018, 9:2924.

3. Radin DP, Tsirka SE: Interactions between Tumor Cells, Neurons, and Microglia in the Glioma Microenvironment. International journal of molecular sciences 2020, 21(22).

4. Zhang H, Li X, Li Y, Chen B, Zong Z, Shen L: An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas. Frontiers in immunology 2020, 11:60341.

5. Blum A, Wang P, Zenklusen JC: SnapShot: TCGA-Analyzed Tumors. Cell 2018, 173(2):530.

6. Gong J, Li R, Chen Y, Zhuo Z, Chen S, Cao J, Zhang Q, Chong Y, Hu B: HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues. Briefings in bioinformatics 2021, 22(5).

7. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al.: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(43):15545–15550.

8. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al.: Molecular portraits of human breast tumours. Nature 2000, 406(6797):747–752.

9. Zhao C, Sahni S: String correction using the Damerau-Levenshtein distance. BMC bioinformatics 2019, 20(Suppl 11):277.

10. Omuro A, DeAngelis LM: Glioblastoma and other malignant gliomas: a clinical review. Jama 2013, 310(17):1842–1850.

11. Liu T, Zhang H, Yi S, Gu L, Zhou M: Mutual regulation of MDM4 and TOP2A in cancer cell proliferation. Molecular oncology 2019, 13(5):1047–1058.

12. Wang M, Cui Y, Cai Y, Jiang Y, Peng Y: Comprehensive Bioinformatics Analysis of mRNA Expression Profiles and Identification of a miRNA-mRNA Network Associated with the Pathogenesis of Low-Grade Gliomas. Cancer management and research 2021, 13:5135–5147.

13. Duan J, Huang W, Shi H: Positive expression of KIF20A indicates poor prognosis of glioma patients. OncoTargets and therapy 2016, 9:6741–6749.

14. Kikuchi R, Ueda R, Saito K, Shibao S, Nagashima H, Tamura R, Morimoto Y, Sasaki H, Noji S, Kawakami Y et al.: A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma. Journal of clinical medicine 2019, 8(2).

15. Geng RX, Li N, Xu Y, Liu JH, Yuan FE, Sun Q, Liu BH, Chen QX: Identification of Core Biomarkers Associated with Outcome in Glioma: Evidence from Bioinformatics Analysis. Disease markers 2018, 2018:3215958.

16. Wang D, Sun H, Li X, Wang G, Yan G, Ren H, Hou B: CCNB2 is a novel prognostic factor and a potential therapeutic target in Low-grade glioma (LGG). Bioscience reports 2021.

17. Wang Y, Zhang H, Wang M, He J, Guo H, Li L, Wang J: CCNB2/SASP/Cathepsin B & PGE2 Axis Induce Cell Senescence Mediated Malignant Transformation. International journal of biological sciences 2021, 17(13):3538–3553.

18. Xi X, Chu Y, Liu N, Wang Q, Yin Z, Lu Y, Chen Y: Joint bioinformatics analysis of underlying potential functions of hsa-let-7b-5p and core genes in human glioma. Journal of translational medicine 2019, 17(1):129.

19. Du R, Huang C, Liu K, Li X, Dong Z: Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. Molecular cancer 2021, 20(1):15.

20. Hu ZD, Jiang Y, Sun HM, Wang JW, Zhai LL, Yin ZQ, Yan J: KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers. BioMed research international 2021, 2021:2676745.

21. Thankamony AP, Murali R, Karthikeyan N, Varghese BA, Teo WS, McFarland A, Roden DL, Holliday H, Konrad CV, Cazet A et al.: Targeting the Id1-Kif11 Axis in Triple-Negative Breast Cancer Using Combination Therapy. Biomolecules 2020, 10(9).

22. Zhou J, Chen WR, Yang LC, Wang J, Sun JY, Zhang WW, He ZY, Wu SG: KIF11 Functions as an Oncogene and Is Associated with Poor Outcomes from Breast Cancer. Cancer research and treatment 2019, 51(3):1207–1221.

23. Song Z, Pan Y, Ling G, Wang S, Huang M, Jiang X, Ke Y: Escape of U251 glioma cells from temozolomide-induced senescence was modulated by CDK1/survivin signaling. American journal of translational research 2017, 9(5):2163–2180.
24. Lee E, Pain M, Wang H, Herman JA, Toledo CM, DeLuca JG, Yong RL, Paddison P, Zhu J: Sensitivity to BUB1B Inhibition Denes an Alternative Classification of Glioblastoma. Cancer research 2017, 77(20):5518–5529.
25. Venere M, Miller TE, Rich JN: Mitotic control of cancer stem cells. Cancer discovery 2013, 3(2):141–144.
26. Zhang Y, Li J, Yi K, Feng J, Cong Z, Wang Z, Wei Y, Wu F, Cheng W, Samo AA et al: Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma. Proceedings of the National Academy of Sciences of the United States of America 2019, 116(14):6975–6984.

**Tables**

Table 1. The relationship between LGG subtypes and clinical features.

| Covariates                          | Total      | C1         | C2         | C3         | P-value |
|-------------------------------------|------------|------------|------------|------------|---------|
| Age                                 |            |            |            |            | 0.0362  |
| <=65                                | 478(93.73%)| 130(90.28%)| 104(92.04%)| 244(96.44%)|         |
| >65                                 | 32(6.27%)  | 14(9.72%)  | 9(7.96%)   | 9(3.56%)   |         |
| Gender                              |            |            |            |            | 0.5333  |
| FEMALE                              | 228(44.71%)| 60(41.67%) | 55(48.67%) | 113(44.66%)|         |
| MALE                                | 282(55.29%)| 84(58.33%) | 58(51.33%) | 140(55.34%)|         |
| Grade                               |            |            |            |            | 0.00012 |
| G2                                  | 248(48.63%)| 49(34.03%) | 30(26.55%) | 169(66.8%) |         |
| G3                                  | 261(51.18%)| 94(65.28%) | 83(73.45%) | 84(33.2%)  |         |
| Unknown                             | 1(0.2%)    | 1(0.69%)   | 0(0%)      | 0(0%)      |         |
| First presenting symptom            |            |            |            |            |         |
| Headaches                           | 105(20.59%)| 34(23.61%) | 20(17.7%)  | 51(20.16%) | 0.1188  |
| Mental Status Changes               | 39(7.65%)  | 12(8.33%)  | 7(6.19%)   | 20(7.91%)  |         |
| Motor/Movement Changes              | 38(7.45%)  | 8(5.56%)   | 12(10.62%) | 18(7.11%)  |         |
| Seizures                            | 245(48.04%)| 71(49.31%) | 58(51.33%) | 116(45.85%)|         |
| Sensory Changes                     | 18(3.53%)  | 4(2.78%)   | 5(4.42%)   | 9(3.56%)   |         |
| Visual Changes                      | 12(2.35%)  | 7(4.86%)   | 1(0.88%)   | 4(1.58%)   |         |
| Unknow                              | 1(0.2%)    | 1(0.69%)   | 0(0%)      | 0(0%)      |         |
| Left                                | 248(48.63%)| 70(48.61%) | 55(48.67%) | 123(48.62%)| 0.8295  |
| Midline                             | 6(1.18%)   | 3(2.08%)   | 1(0.88%)   | 2(0.79%)   |         |
| Right                               | 251(49.22%)| 69(47.92%) | 57(50.44%) | 125(49.41%)|         |
| Unknown                             | 5(0.98%)   | 2(1.39%)   | 0(0%)      | 3(1.19%)   |         |
| Tumor location                      |            |            |            |            |         |
| Posterior Fossa, Brain Stem         | 1(0.2%)    | 1(0.69%)   | 0(0%)      | 0(0%)      | 0.1589  |
| Posterior Fossa, Cerebellum         | 2(0.39%)   | 1(0.69%)   | 0(0%)      | 1(0.4%)    |         |
| Supratentorial, Frontal Lobe        | 300(58.82%)| 74(51.39%) | 67(59.29%) | 159(62.85%)|         |
| Supratentorial, Not Otherwise Specified | 8(1.57%) | 4(2.78%) | 1(0.88%) | 3(1.19%) |         |
| Supratentorial, Occipital Lobe      | 8(1.57%)   | 2(1.39%)   | 4(3.54%)   | 2(0.79%)   |         |
| Supratentorial, Parietal Lobe       | 47(9.22%)  | 11(7.64%)  | 12(10.62%) | 24(9.49%)  |         |
| Supratentorial, Temporal Lobe       | 143(28.04%)| 51(35.42%) | 28(24.78%) | 64(25.3%)  |         |
| Unknown                             | 1(0.2%)    | 0(0%)      | 1(0.88%)   | 0(0%)      |         |
Table 2. Results of COX regression analysis regarding 21 gene sets affecting the survival prognosis of LGG patients.

| Id                                                                 | Coef     | HR        | HR.95L    | HR.95H    | p-value   |
|-------------------------------------------------------------------|----------|-----------|-----------|-----------|-----------|
| T_GSE14415_INduced_TREG_Vs_FAILED_INduced_TREG_DN               | 49.62146 | 3.55E+21  | 2.86E+10  | 4.40E+32  | 0.00014   |
| T_HALLMARK_G2M_CHECKPOINT                                       | 77.5229  | 4.65E+33  | 7.59E+15  | 2.85E+51  | 0.00207   |
| T_GSE9650_NAIVE_Vs_EFF_CD8_TCELL_DN                             | 38.75154 | 6.75E+16  | 0.000117  | 3.91E+37  | 0.012132  |
| T_GSE37532_LT_Vs_PPARG_KO_Visceral_AdiPose_TISSUE_TREG_UP       | -94.9046 | 6.07E-42  | 1.91E-62  | 1.93E-21  | 8.14E-05  |
| T_GSE27241_LT_vs_Rorgt_Ko_TH17_Polarized_CD4_TCELL_UP           | 39.39034 | 1.28E+17  | 6517.725  | 2.51E+30  | 0.011658  |
| T_GSE33162_HDAC3_Ko_Vs_HDAC3_Ko_MACROPHAGE_DN                   | -66.5605 | 1.24E-29  | 5.36E-44  | 2.87E-15  | 8.00E-05  |
| T_GSE25088_LT_Vs_STAT6_Ko_MACROPHAGE_IL4_STIM_DN                | -40.7207 | 2.07E-18  | 6.87E-35  | 0.062128  | 0.035423  |
| T_GSE24634_TREG_vs_TCONv_POST_DAY3_IL4_CONVERSION_UP            | -46.4434 | 6.76E-21  | 4.59E-39  | 0.009958  | 0.029562  |
| T_GSE22886_UNSTIM_Vs_IL2_STIM_NKCELL_DN                         | -57.048  | 1.68E-25  | 1.21E-42  | 2.33E-08  | 0.004616  |
| T_GSE30962_PRIMARY_Vs_SECONDARY_ACUTE_LCMV_INF_CD8_TCELL_UP     | -43.4696 | 1.32E-19  | 8.20E-35  | 0.000213  | 0.014972  |
| T_GSE36476_CTRL_vs_TSST_ACT_72H_MEMORY_CD4_TCELL_OLD_DN         | -88.1892 | 5.01E-39  | 4.22E-63  | 5.95E-15  | 0.001821  |
| T_GSE19941_LPS_Vs_LPS_And_IL10_STIM_IL10_Ko_MACROPHAGE_UP       | 67.2787  | 1.65E+29  | 3.2E+13   | 8.55E+44  | 0.000268  |
| T_GSE22601_DOUBLE_POSITIVE_Vs_CD4_SINGLE_POSITIVE_THYMOCYTE_DN  | 39.84654 | 2.02E+17  | 7.53E-07  | 5.41E+40  | 0.047695  |
| T_GSE24634_TREG_vS_TCONv_POST_DAY7_IL4_CONVERSION_UP             | -41.8642 | 6.59E-19  | 9.90E-34  | 0.000438  | 0.006214  |
| T_GSE45365_LT_vS_IFNAR_Ko_BCELL_DN                              | -40.4809 | 2.63E-18  | 3.08E-27  | 2.24E-09  | 0.000114  |
| T_GSE36476_CTRL_vS_TSST_ACT_72H_MEMORY_CD4_TCELL_YOUNG_DN       | 92.92481 | 2.27E+40  | 2.47E+18  | 2.09E+62  | 0.000317  |
| T_GSE21063_CTRL_vS_ANTIGM_STIM_BCELL_NFATC1_Ko_8H_DN            | 67.73301 | 2.61E+29  | 7.8E+11   | 8.71E+46  | 0.001002  |
| T_GSE25088_LT_vS_STAT6_Ko_MACROPHAGE_DN                         | 35.21672 | 1.97E+15  | 0.027354  | 1.42E+32  | 0.025364  |
| T_KAECH_NAIVE_vS_DAY8_EFF_CD8_TCELL_DN                           | -38.2487 | 2.45E-17  | 8.55E-40  | 700892    | 0.001712  |
| T_GSE39110_DAY3_vS_DAY6_POST_IMMUNIZATION_CD8_TCELL_DN          | 35.6956  | 3.18E+15  | 0.073798  | 1.37E+32  | 0.047761  |
| T_GSE22313_HEALTHY_vS_SLE_MOUSE_CD4_TCELL_DN                    | -19.772  | 2.59E-09  | 3.42E-17  | 0.19599   | 0.032677  |

Figures
LGG datasets from TCGA

[Flowchart about our research]

Figure 1
Flowchart about our research.

[Heat map]

Figure 2
Heat map of the enrichment fraction of immunological and marker genomes in LGG tumor samples. Immunological and marker genomes were downloaded from GSEA.
Figure 3

LGG subtype identification. A. Use the factoextra package to perform clusters analysis. B. Sample composition diagram of the 3 cancer subtypes. C. K-M curves of different cancer subtypes. D. Cancer Subtypes' Silhouette width plots.

Figure 4
Differential gene sets' expression of clinical features and cancer subtypes.

Figure 5
Venn diagram, a common set of differential genes for the three cancer subtypes.

Figure 6
Heat map of the relationship between the expression of gene sets affecting patient survival prognosis, and individual clinically relevant information.

Figure 7
High risk score among LGG patients were associated with low overall survival. p-value < 0.05 was considered statistically significant (Various sets of genes affecting patient survival prognosis).
Figure 8

High risk score among LGG patients were associated with low overall survival. p-value < 0.05 was considered statistically significant (The individual gene sets of Figure 7 together comprise the survival prognostic model).

Figure 9

Biological functional network. A. Functional enrichment network of individual genes in 21 gene sets affecting patient survival prognosis. B. Core genes in a set of 21 genes (Module 1). C. Core genes of 21 gene sets (Module 2).